Physician profile
Silvana Toscano
NPI 1255882593
$2,709.79
in general payments reported to CMS, 2019-2025
24 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $72.09 · 2022: $422 · 2023: $1,008 · 2024: $58.85 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,102.64 |
| Education | $113.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $404.85 | 2024-2025 | Nuvent, Propel |
| Abbvie INC. | $361.84 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $339.71 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $250.46 | 2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $220.43 | 2022-2023 | Austedo Xr, Uzedy |
| Optinose US, INC. | $205.63 | 2025 | |
| Janssen Pharmaceuticals, INC | $166.30 | 2022-2023 | Spravato |
| Genzyme Corporation | $111.02 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.54 | 2022-2023 | Trintellix |
| Glaxosmithkline, LLC. | $60.09 | 2025 | Nucala |
| Sanofi-Aventis U.S. LLC | $56.99 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $55.91 | 2023 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $52.97 | 2022 | |
| Almatica Pharma LLC | $51.51 | 2023 | Loreev Xr, Sertraline Hcl |
| Corium, LLC | $49.01 | 2023 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $43.25 | 2023-2025 | Sublocade, Perseris |
| Genentech USA, INC. | $33.95 | 2025 | Xolair |
| Neurocrine Biosciences, INC. | $32.86 | 2022 | |
| Arthrex, INC. | $24.00 | 2024 | |
| Alkermes, INC. | $23.15 | 2023 | Vivitrol |
| Redhill Biopharma INC. | $17.79 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.54 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.32 | 2025 | Xhance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silvana Toscano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.